10 million Euros to keep moving
Enlarge image


10 million Euros to keep moving

21.11.2012 - The Dutch biotech company Kiadis BV has raised €10m in a financing round led by its largest investor.

This round was led by the Company’s largest shareholder Life Sciences Partners and supported by a large investment from DFJ-Esprit, a tech investor based in London. Other financiers included Alta Partners (San Francisco), Quest for Growth (Netherlands) and NOM, the regional development for Northern Netherlands. Kiadis Pharma is specialised on developing treatments for blood cancer and related diseases.

The company's most advanced project is ATIR, which focuses on donor immune cells in which the alloreactive T-cells that would otherwise attack the patient’s body have been selectively eliminated. The cells are infused in the patient about 30 days after the patient has undergone a stem cell transplantation in which all immune cells have been depleted from the graft of the donor. 

The financing will enable Kiadis Pharma to perform a confirmatory multi-centre Phase II proof-of-concept study with its lead product and to prepare a pivotal Phase II/III study. Manfred Ruediger, CEO of Kiadis Pharma and Venture Partner at Kiadis shareholder LSP, commented: “We are delighted with the enthusiastic support from existing and new investors, which attests to the exciting clinical data generated for ATIR so far and to the progress the company has achieved over the last year. We are determined to advance ATIR in close cooperation with our clinical investigators in North America and Europe.” Kiadis Pharma merged in 2007 with the Canadian Biotech Celmed Biosciences.



12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK40.4%
  • ZEALAND PHARMA (DK)160.00 DKK31.1%
  • THROMBOGENICS (B)3.98 EUR30.1%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5137.5%
  • CHRONTECH PHARMA (S)0.34 SEK466.7%
  • GALAPAGOS (B)38.68 EUR247.8%


  • NEOVACS (F)0.75 EUR-76.1%
  • BIOTEST (D)19.54 EUR-72.9%
  • EVOCUTIS (UK)0.15 GBP-68.7%

No liability assumed, Date: 12.10.2015